TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fetal Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: documented hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Total PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent Free PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Prostate Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Ongoing Use and Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success with syncing the reading on the Onyx Glucose Meter and App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success in accessing and using Smart Reminders Feature in the Onyx App System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success at accessing the Expanded Graph and My Readings View in the Onyx App System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success in interpreting the Expanded Graph and My Readings View in the Onyx App System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: National Institute of Health Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Responder Rate for Partial Onset Seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objectively Measured Cognitive Function Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objectively Measured Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objectively Measured Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: All-cause death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: All-cause death, MI or need for cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Plasma AUCinf of PF-00299804 when given alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUCinf of PF-00299804 when given in combination with paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of PF-00299804 when given alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical diagnosis of brucella spondylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary (dys)function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean interval from diagnosis to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Circulating EPCs Number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade III or greater toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Fever >39°C
Endpoint domain: Adverse events/effects
Primary endpoint: changes in negative symptoms measured on SANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline on neurocognitive battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levator ani muscle space coordinates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iron profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency and magnitude of subclinical systolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from Major adverse limb event (MALE)
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic and endocrine metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnosis of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis of other childhood respiratory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 2-back verbal working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients who achieve curative (R0) surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in muscle stiffness and activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quantitative determination of HLA-peptide tetramer-binding assay (TBA) pp65
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CMV viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CMV-associated complications
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression Free Survival Rate at 24 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Time to Meet Physical Therapy Discharge Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Huntington's Disease Rating Scale (UHDRS) - total score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the International Cooperative Ataxia Rating Scale (ICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Serum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gate speed of time-distance gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep quality score during past month before admission
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep quality score during past day of hospitalization
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep quality score during past five days after cardiac catheterization
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in fasting plasma glucose from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose of PR-104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail making test (TMT) 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail making test (TMT) 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Month backwards test (MBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Superiority of umbilical cord care methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Abdominal fat re-distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dislocation recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Association of total fat with weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean, 24-hour Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean, 24-hour Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Ischemic Cardiac Events
Endpoint domain: Adverse events/effects
Primary endpoint: Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Death, Reinfarction, Stroke, or Stent Thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Lymph Nodes Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: delta13C Added Sugar Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of indacaterol compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft healing assessed by color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft healing assessed by texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft healing assessed by inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation heterogeneity (Sacin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Academic Achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerable Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responder subjects at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cholera toxin-specific IgA and IgG antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dosage of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of patients with obstruction release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function measured by Flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual analogue pain (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQoL Questionnaire (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of heat symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edmonton Symptom Assessment Scale (ESAS) Symptom Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal Health Questionnaire-9 (PHQ-9) Depression Screen
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects With at Least One Severe Solicited Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: mean difference in pain scores postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance of functional tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to first symptomatic or asymptomatic event of AFIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in MADRS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Vincristine-induced Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Severe Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related major complications
Endpoint domain: Adverse events/effects
Primary endpoint: P2Y12 Reaction Units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Computerized lung sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes on glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients decolonized following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: radiographic bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypophosphatemia related to sorafenib treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of drug sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma concentration of piperacillin-tazobactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of cefazolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-field toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Positive and Negative Symptom Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression scale (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extrapyramidal Symptom Rating Scale (ESRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive functions assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in percent breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Active Knee Extension Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tumor blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater Reliability Using a Lower Facial Shape Classification (LFSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater Reliability Using a Lower Facial Shape Classification (LFSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of cardiac output changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients agreeing to participate in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of enrolled patients completing CPET and 6MWD test without significant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of recruited patients wearing Fitbit for at least 8 hours per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with successfully recorded data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intrabronchial airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean population Inhibitory Concentration for 50% Effect (IC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Transition Readiness Assessment Questionnaire (TRAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety (numeric cellulitis score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cessation of Skin Detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxysterol levels in seminal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of severe acute graft-versus-host-disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of transplant-related nonrelapse mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: 6-month probability of survival
Endpoint domain: Mortality/survival
Primary endpoint: Radial artery occlusion (RAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area under the plasma concentration time curve from Baseline to time of last detectable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero up to infinity (AUC(0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of the tested single sc doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of clients negative for malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NF-κB pathway expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability to deliver adequate measurement data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: KOOS Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Serum Calcium to Phosphorus ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brachial artery flow mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV RNA Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of obstructive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Spent in 'on' State Without Troublesome Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time of 24-hour intragastric pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC of 24-hour intragastric pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of care received by patients
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Inhibition of PSTAT3 (Count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffuse near infrared spectroscopy measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Demonstrate no or Minimal Opioid Use at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Remain HIV Negative at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence in Care at 3 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline Glucose at 180 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in glucagon release (AUC0-180 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Testosterone Serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Association of matrix metalloproteinases with atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes